4 Analysts Have This To Say About Zoetis
Portfolio Pulse from Benzinga Insights
Four analysts have recently updated their ratings on Zoetis (NYSE:ZTS), showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target for Zoetis is now $234.00, marking a 6.36% increase from the previous target of $220.00. Analysts from Piper Sandler, Barclays, Goldman Sachs, and Jefferies have raised their price targets, reflecting optimism about Zoetis's future performance. The company, a leader in animal health products, has shown strong financial health with a positive revenue trend, high net margin, and exceptional ROE and ROA, despite a high debt-to-equity ratio.
February 20, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zoetis receives positive analyst ratings with an increased average price target of $234.00. The company's strong financial performance and market leadership in animal health products contribute to the optimistic outlook.
The increase in the average price target to $234.00, up from $220.00, reflects analysts' optimism about Zoetis's future performance. This optimism is supported by the company's positive revenue trend, high net margin, and exceptional ROE and ROA, despite a high debt-to-equity ratio. The unanimous positive adjustments in ratings and price targets by analysts from reputable firms further bolster confidence in the stock's short-term prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100